Synthesis and Anticancer Activity of Biologically Active Heterocyclic Compounds
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: 25 October 2025 | Viewed by 126
Special Issue Editors
Interests: organic synthesis; pharmaceutics; heterocyclic compounds
Special Issue Information
Dear Colleagues,
Cancer remains a pressing public health challenge. According to data from the World Health Organization, almost 10 million people died of cancer in 2020. Chemotherapy is the most common type of cancer treatment, but it also affects healthy cells and has serious side effects. Treatment using low-molecular-weight compounds that target a specific enzyme or receptor, thereby blocking oncogenic signaling and interfering with cancer cell proliferation, is becoming increasingly popular. Therefore, the search for new heterocyclic synthetic molecules with strong activity and low toxicity has become an important endeavor in the field of malignant tumor treatment. Heterocyclic compounds also attract significant attention in organic synthesis more broadly owing to their wide range of biological activities. Despite the significant amount of research already conducted on biologically active heterocyclic compounds, their potential continues to drive a growing number of new applications, which we anticipate will be explored in this Special Issue.
Dr. Birutė Grybaitė
Dr. Rita Vaickelionienė
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- heterocyclic compounds
- five- or six-membered heterocycles
- oxygen- and nitrogen-based heterocycles
- sulfur- and nitrogen-based heterocycles
- azoles
- small molecules
- anticancer activity
- cell lines
- cytotoxicity
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
